Laboratory monitoring of anticoagulation: Where do we stand?

Seminars in Thrombosis and Hemostasis

Volumn 35, Issue 1, 2009, Pages 34-41

  Tripodi, Armando ^a,c   Van Den Besselaar, Antonius ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NONE   (Italy)

Author keywords

Fondaparinux; Heparin; Low molecular weight heparin; New anticoagulant drugs; Vitamin K antagonists

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; ARGATROBAN; AVIDIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DABIGATRAN ETEXILATE; FONDAPARINUX; HEPARIN; HIRUDIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE SULFATE; RECOMBINANT HIRUDIN; RIVAROXABAN; THROMBIN INHIBITOR;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLOOD CLOTTING TIME; CLINICAL LABORATORY; DISEASE SEVERITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; PATIENT MONITORING; PRIORITY JOURNAL; PROPHYLAXIS; PROTHROMBIN TIME; RECURRENT DISEASE; REVIEW; THROMBUS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION; CLINICAL TRIALS AS TOPIC; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; MONITORING, PHYSIOLOGIC; MORPHOLINES; POLYSACCHARIDES; PROTHROMBIN TIME; PULMONARY EMBOLISM; PYRAZOLES; PYRIDONES; THIOPHENES; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS; VITAMIN K;

EID: 63149098718     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1214146     Document Type: Review

References (62)

1. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004;117:19-25
2. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7
3. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999;159:445-453
4. Piovella F, Wang CJ, Lu H, et al. Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. J Thromb Haemost 2005;3:2664-2670
5. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJAmerican College of Chest Physicians. Anti-thrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(Suppl): 454S-545S
6. Spyropoulos AC. Brave new world: the current and future use of novel anticoagulants. Thromb Res 2008;123(Suppl 1):529-535
7. Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med 2003;3:221-230
8. Paul B, Oxley A, Brigham K, Cox T, Hamilton PJ. Factor II, VII, IX and X concentrations in patients receiving long term warfarin. J Clin Pathol 1987;40:94-98
9. Quick AJ, Stanley-Brown M, Bancroft FW. A study of the coagulation defect in hemophilia and in jaundice. Am J Med Sci 1935;190:501-511
10. Blombäck M, Abildgaard U, van den Besselaar AM, et al. Nomenclature of quantities and units in thrombosis and haemostasis (recommendation 1993). A collaborative project of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH/SSC) and the Commission/Committee on Quantities and Units (in Clinical Chemistry) of the International Union of Pure and Applied Chemistry-International Federation of Clinical Chemistry (IUPAC-IFCC/CQU(CC)). Thromb Haemost 1994;71:375-394
11. Van den Besselaar AMHP. International standardization of laboratory control of oral anticoagulant therapy: a survey of thromboplastin reagents used for prothrombin time testing. J Heart Valve Dis 1993;2:42-52
12. Loeliger EA. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Acta Haematol 1984;72:405-407
13. Expert WHO. Committee on Biological Standardization. Guidelines for Thromboplastins and Plasma Used to Control Oral Anticoagulant Therapy. WHO Technical Report Series no. 889 Geneva, Switzerland: WHO; 1999:64-93
14. Tomenson JA. A statistician's independent evaluation. In: van den Besselaar AMHP, Gralnick HR, Lewis SM, eds. Thromboplastin Calibration and Oral Anticoagulant Control. The Hague: Martinus Nijhoff Publishers; 1984:87-108
15. Gogstad GO, Wadt J, Smith P, Brynildsrud T. Utility of a modified calibration model for reliable conversion of thromboplastin times to international normalized ratios. Thromb Haemost 1986;56:178-182
16. Leichsenring I, Plesch W, Unkrig V, et al. Multicentre ISI assignment and calibration of the INR measuring range of a new point-of-care system designed for home monitoring of oral anticoagulant therapy. Thromb Haemost 2007;97:856-861
17. Tripodi A, Breukink-Engbers WGM, van den Besselaar AMHP. Oral anticoagulant monitoring by laboratory or near-patient testing: what a clinician should be aware of. Semin Vasc Med 2003;3:243-254
18. Kitchen S, Preston FE. Monitoring oral anticoagulant treatment with the TAS near-patient test system: comparison with conventional thromboplastins. J Clin Pathol 1997;50:951-956
19. Tripodi A, Chantarangkul V, Clerici M, Negri B, Mannucci PM. Determination of the international sensitivity index of a new near-patient testing device to monitor oral anticoagulant therapy. Overview of the assessment of conformity to the calibration model. Thromb Haemost 1997;78:855-858
20. Taborski U, Braun SL, Völler H. Analytical performance of the new coagulation monitoring system INRatio for the determination of INR compared with the coagulation monitor Coaguchek S and an established laboratory method. J Thromb Thrombolysis 2004;18:103-107
21. Tripodi A, Chantarangkul V, Bressi C, Mannucci PM. International sensitivity index calibration of the near-patient testing prothrombin time monitor, protime. Am J Clin Pathol 2003;119:241-245
22. Braun S, Watzke H, Hasenkam JM, et al. Performance evaluation of the new CoaguChek XS system compared with the established CoaguChek system by patients experienced in INR-self management. Thromb Haemost 2007;97:310-314
23. Tripodi A. Prothrombin time international normalized ratio monitoring by self-testing. Curr Opin Hematol 2004;11:141-145
24. Tripodi A, Arbini AA, Chantarangkul V, Bettega D, Mannucci PM. Are capillary whole blood coagulation monitors suitable for control of oral anticoagulant treatment by the international normalized ratio? Thromb Haemost 1993;70:921-924
25. Poller L, Keown M, Chauhan N, et al. European Concerted Action on Anticoagulation (ECAA): multicentre international sensitivity index calibration of two types of point of care prothrombin time monitor systems. Br J Haematol 2002;116:844-850
26. Van den Besselaar AMHP, Hoekstra MMCL, van der Meer FJM. Quality control of CoaguChek test strips in the Netherlands. Thromb Haemost 2007;97:323-324
27. Meijer P, Kluft C, Poller L, et al. A national field study of quality assessment of CoaguChek point-of-care testing prothrombin time monitors. Am J Clin Pathol 2006;126:756-761
28. Kitchen S, Kitchen D, Jennings I, Woods T, Walker I. Quality assessment of CoaguChek point-of-care international normalized ratio monitors: a note of caution. Clin Chem 2007;53:1555-1556
29. Murray ET, Jennings I, Kitchen D, Kitchen S, Fitzmaurice DA. Quality assurance for oral anticoagulation self management: a cluster randomized trial. J Thromb Haemost 2008;6:464-469
30. Petitou M, Casu B, Lindahl U. 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie 2003;85:83-89
31. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324-327
32. Cuker A, Ptashkin B, Konkle BA, et al. Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time. J Thromb Haemost 2009;7:80-85
33. Liepman CI, Koerber JM, Mattson JC, Westley SJ, Smythe MA. Comparing methods of establishing the aPTT therapeutic range of heparin. Ann Pharmacother 2003;37:794-798
34. Kitchen S, Theaker J, Preston FE. Monitoring unfractionated heparin therapy: releationship between eight anti-Xa assays and a protamine titration assay. Blood Coagul Fibrinolysis 2000;11:137-144
35. Ignatovic V, Summerhayes R, Gan A, et al. Monitoring unfractionated heparin (UFH) therapy: which anti Xa assay is appropriate? Thromb Res 2007;120:347-351
36. Al Dieri R, Alban S, Béguin S, Hemker HC. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2004;2:1395-1401
37. Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight heparin. Thromb Haemost 2008;99:807-818
38. Boneu B. Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost 1994;72:330-334
39. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998;122:799-807
40. Harenberg J. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes J Thromb Haemost 2004;2:547-550
41. Bounameaux H, de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No J Thromb Haemost 2004;2:551-554
42. Bara L, Combe-Tamzali S, Conard J, Horellou MH, Samama M. Laboratory monitoring of a low molecular weight heparin (enoxaparin) with a new clotting test (Heptest). Haemostasis 1987;17:127-133
43. Kitchen S, Iampietro R, Woolley AM, Preston FE. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost 1999;82:1289-1293
44. Kovacs MJ, Keeney M, MacKinnon K, Boyle E. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 1999;21:55-60
45. Sié P, Aillaud MF, de Prost D, et al. Measurement of low molecular weight heparin ex vivo activities in clinical laboratories using various anti-Xa assays: interlaboratory variability and requirement for an agreed low molecular weight heparin standard. Thromb Haemost 1987;58:879-883
46. Boneu B, Faruel-Bille V, Pierrejean D, Gabaig AM. Limitations of the chronometric assays to determine plasma antifactor Xa activity during low molecular weight heparin therapy. Nouv Rev Fr Hematol 1991;33:287-291
47. Kuhle S, Lau A, Bajzar L, et al. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study. Br J Haematol 2006;134:526-531
48. Petitou M, Lormeau JC, Choay J. Chemical synthesis of glycosaminoglycans: new approaches to antithrombotic drugs. Nature 1991;350(6319, Suppl):30-33
49. Bauer KA. New anticoagulants. Hematology (Am Soc Hematol Educ Program) 2006:450-456
50. Calatzis A, Peetz D, Haas S, Spannagl M, Rudin K, Wilmer M. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. Am J Clin Pathol 2008;130:446-454
51. Harder S, Parisius J, Picard-Willems B. Monitoring direct FXa-inhibitors and fondaparinux by prothrombinase-induced clotting time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb Res 2008;123:395-403
52. Gatt A, van Veen JJ, Woolley AM, Kitchen S, Cooper P, Makris M. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost 2008;100:350-355
53. Walenga JM, Jeske WP, Fareed J. Short- and long-acting synthetic pentasaccharides as antithrombotic agents. Expert Opin Investig Drugs 2005;14:847-858
54. Spyropoulos AC. Investigational treatments of venous thromboembolism. Expert Opin Investig Drugs 2007;16:431-440
55. Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]- 1,3-oxazolidin-5-yl}methyl) thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005;48:5900-5908
56. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-880
57. Pinto DJ, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl)-7- oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c] pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007;50:5339-5356
58. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002;45:1757-1766
59. Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb 2003-2004;33:173-183
60. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI; American College of Chest Physicians. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). [Erratum in: Chest 2008;134:473] Chest 2008;133(6, Suppl):141S-159S
61. Tripodi A, Chantarangkul V, Arbini AA, Moia M, Mannucci PM. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents. Thromb Haemost 1993;70:286-288
62. Hemker HC, Al Dieri R, Béguin S. Laboratory monitoring of low-molecular-weight heparin therapy - part II. Monitoring LMWH therapy? For the moment a non-question J Thromb Haemost 2005;3:571-573